L-733,060

L-733,060
Clinical data
ATC code
  • None
Identifiers
IUPAC name
  • (2S,3S)-3-{[3,5-bis(Trifluoromethyl)benzyl]oxy}-2-phenylpiperidine
CAS Number
PubChem CID
ChemSpider
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC20H19F6NO
Molar mass403.368 g·mol−1
3D model (JSmol)
SMILES
  • c1ccc(cc1)[C@H]2[C@H](CCCN2)OCc3cc(cc(c3)C(F)(F)F)C(F)(F)F
InChI
  • InChI=1S/C20H19F6NO/c21-19(22,23)15-9-13(10-16(11-15)20(24,25)26)12-28-17-7-4-8-27-18(17)14-5-2-1-3-6-14/h1-3,5-6,9-11,17-18,27H,4,7-8,12H2/t17-,18-/m0/s1 ☒N
  • Key:FCDRFVCGMLUYPG-ROUUACIJSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

L-733,060 is a drug developed by Merck which acts as an orally active, non-peptide, selective antagonist for the NK1 receptor, binding with a Ki of 0.08 nM.[1] Only one enantiomer is active which has made it the subject of several asymmetric synthesis efforts.[2][3][4]

L-733,060 has antidepressant[5][6] and anxiolytic effects in animal studies,[7] and reduces both the dopamine release and neurotoxicity produced by methamphetamine and cocaine.[8][9][10][11][12] It shows anti-inflammatory and anti-hepatotoxic effects in animals,[13][14] and counteracts the development of hyperalgesia following nerve injury.[15][16] It also has anticancer effects in a variety of in vitro models.[17][18][19]

See also

References

  1. ↑ Seabrook GR, Shepheard SL, Williamson DJ, Tyrer P, Rigby M, Cascieri MA, et al. (December 1996). "L-733,060, a novel tachykinin NK1 receptor antagonist; effects in [Ca2+]i mobilisation, cardiovascular and dural extravasation assays". European Journal of Pharmacology. 317 (1): 129–35. doi:10.1016/S0014-2999(96)00706-6. PMID 8982729.
  2. ↑ Liu LX, Ruan YP, Guo ZQ, Huang PQ (September 2004). "A general approach to (5S,6R)-6-alkyl-5-benzyloxy-2-piperidinones: application to the asymmetric syntheses of neurokinin substance P receptor antagonist (-)-L-733,061 and (-)-deoxocassine". The Journal of Organic Chemistry. 69 (18): 6001–9. doi:10.1021/jo049166z. PMID 15373484.
  3. ↑ Tsai MR, Chen BF, Cheng CC, Chang NC (March 2005). "A novel and highly regioselective approach to 5-methoxy-6-substituted-3-sulfonyl-delta-enlactams from 5-methoxy-3-sulfonyl glutarimide: synthesis of cis-2-substituted-3-piperidinols". The Journal of Organic Chemistry. 70 (5): 1780–5. doi:10.1021/jo048073e. PMID 15730301.
  4. ↑ Liu RH, Fang K, Wang B, Xu MH, Lin GQ (April 2008). "Concise asymmetric synthesis of (+)-CP-99,994 and (+)-L-733,060 via efficient construction of homochiral syn-1,2-diamines and syn-1,2-amino alcohols". The Journal of Organic Chemistry. 73 (8): 3307–10. doi:10.1021/jo8002979. PMID 18331063.
  5. ↑ Varty GB, Cohen-Williams ME, Hunter JC (February 2003). "The antidepressant-like effects of neurokinin NK1 receptor antagonists in a gerbil tail suspension test". Behavioural Pharmacology. 14 (1): 87–95. doi:10.1097/00008877-200302000-00009. PMID 12576885. S2CID 12218489.
  6. ↑ Wallace-Boone TL, Newton AE, Wright RN, Lodge NJ, McElroy JF (July 2008). "Behavioral and pharmacological validation of the gerbil forced-swim test: effects of neurokinin-1 receptor antagonists". Neuropsychopharmacology. 33 (8): 1919–28. doi:10.1038/sj.npp.1301586. PMID 17912250.
  7. ↑ Varty GB, Cohen-Williams ME, Morgan CA, Pylak U, Duffy RA, Lachowicz JE, et al. (September 2002). "The gerbil elevated plus-maze II: anxiolytic-like effects of selective neurokinin NK1 receptor antagonists". Neuropsychopharmacology. 27 (3): 371–9. doi:10.1016/S0893-133X(02)00313-5. PMID 12225694.
  8. ↑ Kraft M, Noailles P, Angulo JA (June 2001). "Substance P modulates cocaine-evoked dopamine overflow in the striatum of the rat brain". Annals of the New York Academy of Sciences. 937 (1): 121–31. Bibcode:2001NYASA.937..121K. doi:10.1111/j.1749-6632.2001.tb03561.x. PMID 11458533. S2CID 33530777.
  9. ↑ Yu J, Allison S, Ibrahim D, Cadet JL, Angulo JA (June 2002). "Ontogeny of neurokinin-1 receptor mediation of methamphetamine neurotoxicity in the striatum of the mouse brain". Annals of the New York Academy of Sciences. 965 (1): 247–53. Bibcode:2002NYASA.965..247Y. doi:10.1111/j.1749-6632.2002.tb04166.x. PMID 12105100. S2CID 8945982.
  10. ↑ Noailles PA, Angulo JA (June 2002). "Neurokinin receptors modulate the neurochemical actions of cocaine". Annals of the New York Academy of Sciences. 965 (1): 267–73. Bibcode:2002NYASA.965..267N. doi:10.1111/j.1749-6632.2002.tb04168.x. PMID 12105102. S2CID 35161445.
  11. ↑ Yu J, Cadet JL, Angulo JA (November 2002). "Neurokinin-1 (NK-1) receptor antagonists abrogate methamphetamine-induced striatal dopaminergic neurotoxicity in the murine brain". Journal of Neurochemistry. 83 (3): 613–22. doi:10.1046/j.1471-4159.2002.01155.x. PMID 12390523.
  12. ↑ Loonam TM, Noailles PA, Yu J, Zhu JP, Angulo JA (June 2003). "Substance P and cholecystokinin regulate neurochemical responses to cocaine and methamphetamine in the striatum". Life Sciences. 73 (6): 727–39. doi:10.1016/S0024-3205(03)00393-X. PMID 12801594.
  13. ↑ Bang R, Sass G, Kiemer AK, Vollmar AM, Neuhuber WL, Tiegs G (April 2003). "Neurokinin-1 receptor antagonists CP-96,345 and L-733,060 protect mice from cytokine-mediated liver injury". The Journal of Pharmacology and Experimental Therapeutics. 305 (1): 31–9. doi:10.1124/jpet.102.043539. PMID 12649350. S2CID 10595836.
  14. ↑ Bang R, Biburger M, Neuhuber WL, Tiegs G (March 2004). "Neurokinin-1 receptor antagonists protect mice from CD95- and tumor necrosis factor-alpha-mediated apoptotic liver damage". The Journal of Pharmacology and Experimental Therapeutics. 308 (3): 1174–80. doi:10.1124/jpet.103.059329. PMID 14617692. S2CID 11723933.
  15. ↑ Jang JH, Nam TS, Paik KS, Leem JW (April 2004). "Involvement of peripherally released substance P and calcitonin gene-related peptide in mediating mechanical hyperalgesia in a traumatic neuropathy model of the rat". Neuroscience Letters. 360 (3): 129–32. doi:10.1016/j.neulet.2004.02.043. PMID 15082150. S2CID 11970289.
  16. ↑ Rittner HL, Lux C, Labuz D, Mousa SA, Schäfer M, Stein C, Brack A (December 2007). "Neurokinin-1 receptor antagonists inhibit the recruitment of opioid-containing leukocytes and impair peripheral antinociception". Anesthesiology. 107 (6): 1009–17. doi:10.1097/01.anes.0000291454.90754.de. PMID 18043070.
  17. ↑ Muñoz M, Rosso M, Coveñas R, Montero I, González-Moles MA, Robles MJ (June 2007). "Neurokinin-1 receptors located in human retinoblastoma cell lines: antitumor action of its antagonist, L-732,138". Investigative Ophthalmology & Visual Science. 48 (6): 2775–81. doi:10.1167/iovs.05-1591. PMID 17525212.
  18. ↑ Muñoz M, Rosso M, Aguilar FJ, González-Moles MA, Redondo M, Esteban F (April 2008). "NK-1 receptor antagonists induce apoptosis and counteract substance P-related mitogenesis in human laryngeal cancer cell line HEp-2". Investigational New Drugs. 26 (2): 111–8. doi:10.1007/s10637-007-9087-y. PMID 17906845. S2CID 19157206.
  19. ↑ Rosso M, Robles-Frías MJ, Coveñas R, Salinas-Martín MV, Muñoz M (2008). "The NK-1 receptor is expressed in human primary gastric and colon adenocarcinomas and is involved in the antitumor action of L-733,060 and the mitogenic action of substance P on human gastrointestinal cancer cell lines". Tumour Biology. 29 (4): 245–54. doi:10.1159/000152942. PMID 18781096. S2CID 5177634.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.